Cargando…

Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis

INTRODUCTION: We performed a study to determine whether an enrollment sequence effect noted in the PROWESS (recombinant human activated Protein C Worldwide Evaluation in Severe Sepsis) trial exists in the ADDRESS (Administration of Drotrecogin Alfa [Activated] [DrotAA] in Early Stage Severe Sepsis)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laterre, Pierre-François, Macias, William L, Janes, Jonathan, Williams, Mark D, Nelson, David R, Girbes, Amand RJ, Dhainaut, Jean-François, Abraham, Edward
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592745/ https://www.ncbi.nlm.nih.gov/pubmed/18786266 http://dx.doi.org/10.1186/cc7011

Ejemplares similares

Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
por: Levy, Howard, et al.
Publicado: (2005)

Clinical trials in severe sepsis with drotrecogin alfa (activated)
por: Laterre, Pierre-François
Publicado: (2007)

The efficacy of Drotrecogin alfa (activated) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
por: Vincent, J, et al.
Publicado: (2004)

Drotrecogin alfa (activated) in the subgroup of patients with multiple organ dysfunction (MOD) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
por: Vincent, J, et al.
Publicado: (2004)

The incidence of serious bleeding events in a global, single-arm, open-label trial of Drotrecogin alfa (activated) in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
por: Beale, R, et al.
Publicado: (2004)

Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis – practical aspects at the bedside and patient identification
por: Laterre, Pierre-François, et al.
Publicado: (2003)

Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)
por: Dhainaut, J, et al.
Publicado: (2008)

Severe sepsis and drotrecogin alfa (activated) use: results from the PROGRESS registry
por: Beale, R, et al.
Publicado: (2007)

Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death
por: Williams, Mark D, et al.
Publicado: (2006)

Introduction: severe sepsis and drotrecogin alfa (activated)
por: Artigas, Antonio, et al.
Publicado: (2007)

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
por: Bernard, Gordon R, et al.
Publicado: (2003)

Timing of drotrecogin alfa (activated) treatment in severe sepsis
por: Choi, Goda, et al.
Publicado: (2006)

The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
por: Martin, Greg, et al.
Publicado: (2009)

Early treatment with Drotrecogin alfa (activated) was associated with reduced hospital resource use in adult severe sepsis patients with two or more organ dysfunctions at baseline: results from ENHANCE
por: Vincent, J, et al.
Publicado: (2004)

Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)
por: Shorr, Andrew F, et al.
Publicado: (2008)

Statistical analysis plan of PROWESS SHOCK study
por: Thompson, B. Taylor, et al.
Publicado: (2010)

Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies
por: Vincent, Jean-Louis, et al.
Publicado: (2005)

The safety profile of drotrecogin alfa (activated)
por: Fumagalli, Roberto, et al.
Publicado: (2007)

Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)
por: Shorr, Andrew F, et al.
Publicado: (2010)

Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death
por: Friedrich, Jan O, et al.
Publicado: (2006)

Anticoagulant properties of drotrecogin alfa (activated) during hemofiltration in patients with severe sepsis
por: de Pont, Anne CJM, et al.
Publicado: (2009)

Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis
por: Annane, Djillali, et al.
Publicado: (2018)

Practical aspects of treatment with drotrecogin alfa (activated)
por: Camporota, Luigi, et al.
Publicado: (2007)

Increasing microcirculation after drotrecogin alfa (activated)
por: Donati, A, et al.
Publicado: (2007)

Retrospective observational outcomes for drotrecogin alfa (activated)
por: Cameron, C, et al.
Publicado: (2007)

Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death
por: Gupta, Sanjay, et al.
Publicado: (2006)

Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
por: Sadique, M Zia, et al.
Publicado: (2011)

Neuroaxial catheters following abdominal surgery and their impact on the use of Drotrecogin alfa (activated) in sepsis
por: Steel, A, et al.
Publicado: (2004)

Severe sepsis: are PROWESS and PROWESS-SHOCK trials comparable? A clinical and statistical heterogeneity analysis
por: Kalil, Andre C, et al.
Publicado: (2013)

Drotrecogin alfa (activated): down and not out, but not really in either
por: Friedrich, Jan O, et al.
Publicado: (2006)

Use of national guidelines for the introduction of Drotrecogin alfa (activated)
por: Mackenzie, S, et al.
Publicado: (2004)

Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?
por: Friedrich, Jan O, et al.
Publicado: (2006)

Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
por: Costa, Vania, et al.
Publicado: (2007)

Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock
por: Spapen, Herbert, et al.
Publicado: (2010)

Cost effectiveness analysis of drotrecogin alfa (activated) as a treatment for severe sepsis in hospitalised patients
por: Launois, R, et al.
Publicado: (2002)

Drotrecogin alfa in sepsis: analysis of outcomes in a UK district general intensive care unit
por: Pathak, H, et al.
Publicado: (2004)

New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated)
por: Macias, William L, et al.
Publicado: (2005)

Drotrecogin alfa (activated): real-life use and outcomes for the UK
por: Rowan, Kathryn M, et al.
Publicado: (2008)

Drotrecogin alfa: start early, ensure response, stop early!
por: Jog, S, et al.
Publicado: (2008)

Treatment of Severe Sepsis: Where Next? Current and Future Treatment Approaches After the Introduction of Drotrecogin Alfa
por: Rice, Todd W
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_h2ie96vjjq6v73iig12ojgsg00